arsenic has been researched along with ATLL in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bazarbachi, A; Hermine, O; Marçais, A; Nasr, R | 1 |
| Bazarbachi, A; Berry, F; Dassouki, Z; de Thé, H; El Hajj, H; Ezzedine, M; Farid, R; Ghantous, A; Ghavamzadeh, A; Hermine, O; Kchour, G; Kooshyar, MM; Mahmoudi, M; Mortada, M; Nasser, R; Rafatpanah, H; Rahimi, H; Rezaee, R; Shirdel, A; Tarhini, M | 1 |
| Bazarbachi, A; Dassouki, Z; de Thé, H; El Hajj, H; Hermine, O; Jollivet, F; Kfoury, Y; Lallemand-Breitenbach, V; Sahin, U | 1 |
| Bazarbachi, A; de Thé, H; El Hajj, H; Farid, R; Hatoum, H; Hermine, O; Kchour, G; Kooshyar, MM; Mahmoudi, M; Maleki, M; Rafatpanah, H; Rahimi, H; Rezaee, SA; Shirdel, A; Tarhini, M; Wattel, E; Yazdi, MT | 1 |
| Gessain, A; Mahieux, R | 1 |
| Ablain, J; Bazarbachi, A; de Thé, H; El Hajj, H; El-Sabban, M; Hall, W; Hasegawa, H; Hermine, O; Janin, A; Kfoury, Y; Mahfouz, R; Nasr, R; Nicot, C; Saab, ST; Zaatari, G | 1 |
| Bazarbachi, A; Fields, P; Hermine, O; Suarez, F | 1 |
| Arima, T; Hanada, S; Ikeda, R; Ishitsuka, K; Ohno, N; Suzuki, S; Takatsuka, Y; Takeshita, T; Takeuchi, S; Uozumi, K; Utsunomiya, A | 1 |
| Arnulf, B; Bazarbachi, A; Bex, F; de Thé, H; El-Sabban, ME; Hermine, O; Lepelletier, Y; Nasr, R; Rosenwald, A; Staudt, L; Zalloua, P | 1 |
| Arnulf, B; Bazarbachi, A; Brouet, JC; Damaj, G; de Thé, H; Degos, L; Delarue, R; Dombret, H; Fermand, JP; Hermine, O; Lefrère, F; Poupon, J; Rousselot, P; Varet, B | 1 |
| Hermine, O; Mahieux, R | 1 |
| Bazarbachi, A; de Thé, H; Hermine, O; Kfoury, Y; Nasr, R | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Bellon, M; Brown, M; Nicot, C | 1 |
| Aoki, M; Hara, S; Ishitsuka, K; Ogata, K; Suzumiya, J; Tamura, K | 1 |
| Abdallah, M; Bazarbachi, A; Darwiche, N; Dbaibo, GS; de Thé, H; El-Sabban, M; Hermine, O; Kfoury, Y; Kozhaya, L; Nasr, R; Panjarian, S | 1 |
| Jiao, Y; Jin, J; Liu, J; Ni, W; Qian, W; Xu, W; Zhang, W | 1 |
| Augustyniak, C; Evens, AM; Gordon, LI; Gupta, R; Mehta, J; Ziegler, SL | 1 |
| Abboushi, N; Ameisen, JC; Bazarbachi, A; Bex, F; Dbaibo, G; de Thé, H; El-Sabban, ME; Hermine, O; Nasr, R; Quignon, F | 1 |
| Arima, T; Hanada, S; Ishitsuka, K; Uozumi, K; Utsunomiya, A | 1 |
| Al-Hashimi, S; Bazarbachi, A; Bazzi, R; Darwiche, N; de Thé, H; El-Sabban, M; Hermine, O; Nasr, R | 1 |
| Bazarbachi, A; Hermine, O | 1 |
| Brady, JN; Gessain, A; Mahieux, R; Misteli, T; Nicot, C; Olivier, R; Perret, E; Pise-Masison, C | 1 |
| Fatfat, M; Gali-Muhtasib, H; Ghazal, N; Habli, Z; Houssein, M; Khalife, H; Khalil, M; Moodad, S | 1 |
| Gallo, RC | 1 |
6 review(s) available for arsenic and ATLL
| Article | Year |
|---|---|
Overview of Targeted Therapies for Adult T-Cell Leukemia/Lymphoma.
Topics: Adult; Antineoplastic Agents, Immunological; Arsenic Trioxide; Arsenicals; Female; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Receptors, CXCR4; Zidovudine | 2017 |
Adult T-cell leukemia/lymphoma and HTLV-1.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; CD4-Positive T-Lymphocytes; Clinical Trials as Topic; Daclizumab; Drug Resistance, Neoplasm; Endemic Diseases; Female; Gene Products, tax; Genes, pX; Human T-lymphotropic virus 1; Humans; Immunoglobulin G; Immunophenotyping; Immunotherapy; Infant, Newborn; Infectious Disease Transmission, Vertical; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Paraparesis, Tropical Spastic; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2007 |
In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha.
Topics: Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Proliferation; Clinical Trials, Phase II as Topic; Drug Synergism; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Oxides; Tumor Virus Infections | 2005 |
Proapoptotic regimes for HTLV-I-transformed cells: targeting Tax and the NF-kappaB pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Delivery Systems; Gene Expression Regulation; Gene Products, tax; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Nitriles; Oxides; Proteasome Inhibitors; Sulfones; T-Lymphocytes | 2005 |
Treatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Oxides; Retinoids; Tumor Virus Infections; Zidovudine | 2001 |
Research and discovery of the first human cancer virus, HTLV-1.
Topics: Adult; Animals; Antiviral Agents; Arsenic; Cell Proliferation; Cell Transformation, Viral; Host-Pathogen Interactions; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Interferons; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, Transgenic; Viral Proteins; Virus Replication; Zidovudine | 2011 |
3 trial(s) available for arsenic and ATLL
| Article | Year |
|---|---|
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Synergism; Female; Gastrointestinal Diseases; Hematologic Diseases; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Proviruses; Remission Induction; Viral Load; Zidovudine | 2009 |
Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Female; Human T-lymphotropic virus 1; Humans; Injections, Intravenous; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Middle Aged; Oxides; Prognosis; Recurrence; Treatment Outcome; Zidovudine | 2004 |
Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Disease Progression; Female; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Oxides; Recurrence; Salvage Therapy; Thrombocytopenia | 2007 |
16 other study(ies) available for arsenic and ATLL
| Article | Year |
|---|---|
The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.
Topics: Adult; Aged; Arsenic Trioxide; Arsenicals; Cytokines; Female; Gene Expression Profiling; HTLV-I Infections; Humans; Immunologic Factors; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Prospective Studies; Treatment Outcome; Zidovudine | 2013 |
ATL response to arsenic/interferon therapy is triggered by SUMO/PML/RNF4-dependent Tax degradation.
Topics: Antiviral Agents; Apoptosis; Arsenicals; Blotting, Western; Cell Proliferation; Cell Transformation, Viral; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Gene Products, tax; HeLa Cells; Human T-lymphotropic virus 1; Humans; Immunoprecipitation; Interferons; Leukemia-Lymphoma, Adult T-Cell; Nuclear Proteins; Promyelocytic Leukemia Protein; Proteolysis; Sulfhydryl Reagents; SUMO-1 Protein; Sumoylation; Transcription Factors; Tumor Suppressor Proteins; Ubiquitination | 2015 |
Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Cycle; Gene Products, tax; Human T-lymphotropic virus 1; Humans; In Situ Nick-End Labeling; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Mice; Mice, SCID; Mice, Transgenic; Organ Size; Oxides; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Treatment Outcome | 2010 |
How I treat adult T-cell leukemia/lymphoma.
Topics: Anti-Retroviral Agents; Antibodies, Monoclonal; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Hematopoietic Stem Cell Transplantation; HTLV-I Infections; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides | 2011 |
Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line; Enzyme Activation; fas Receptor; G1 Phase; Humans; Leukemia-Lymphoma, Adult T-Cell; Membrane Potentials; Oxides; Poly(ADP-ribose) Polymerases; Receptors, Tumor Necrosis Factor; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2002 |
Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Survival; Cysteine Endopeptidases; Gene Expression Profiling; Gene Products, tax; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; NF-kappa B; Oxides; Tumor Cells, Cultured | 2003 |
Lung infiltration of adult T-cell leukemia cells following the administration of arsenic trioxide. Lung infiltration of ATL by AS(2)O(3).
Topics: Aged; Arsenic Trioxide; Arsenicals; Deltaretrovirus Antibodies; Fatal Outcome; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemic Infiltration; Lung; Male; Oxides | 2006 |
Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1.
Topics: Arsenic Trioxide; Arsenicals; Cell Cycle; Cell Death; Cell Line, Transformed; Docosahexaenoic Acids; Drug Synergism; Drug Therapy, Combination; Emodin; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Oxides; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Transcription Factor AP-1 | 2007 |
Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Ceramides; Glucosyltransferases; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Promyelocytic, Acute; Metabolic Networks and Pathways; Oxides | 2007 |
Telomere attrition and chromosome instability via downregulation of TRF2 contributes to arsenic trioxide-induced apoptosis of human T-Cell leukemia cell line molt-4 cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Line, Tumor; Cell Proliferation; Chromosomal Instability; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Telomerase; Telomere; Telomeric Repeat Binding Protein 2 | 2007 |
Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Central Nervous System Neoplasms; Diphtheria Toxin; Drug Resistance, Neoplasm; Hematologic Neoplasms; Humans; Interferons; Interleukin-2; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Oxides; Recombinant Fusion Proteins; Recurrence; Remission Induction; Transplantation, Homologous; Zidovudine | 2007 |
Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Cell Cycle; Cell Line, Transformed; Cell Transformation, Viral; DNA; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Viral; Gene Products, tax; Human T-lymphotropic virus 1; Humans; I-kappa B Proteins; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Ligases; Macromolecular Substances; Neoplasm Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; T-Lymphocytes; Transcriptional Activation; Tumor Cells, Cultured | 2000 |
Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2 Homologous Antagonist-Killer Protein; Cell Cycle Proteins; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cysteine Proteinase Inhibitors; Drug Screening Assays, Antitumor; G1 Phase; Gene Expression Regulation, Leukemic; Genes, bcl-2; Genes, p53; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Membrane Proteins; Neoplasm Proteins; Oxides; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; T-Lymphocytes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2000 |
Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Transformed; Human T-lymphotropic virus 1; Humans; Leukemia-Lymphoma, Adult T-Cell; Oxides; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; T-Lymphocytes; Tretinoin | 2001 |
Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Caspases; Cell Line, Transformed; Cell Nucleus; Cytochrome c Group; DNA-Binding Proteins; Flow Cytometry; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; Humans; I-kappa B Proteins; Interferon-alpha; Leukemia-Lymphoma, Adult T-Cell; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; NF-kappa B; NF-KappaB Inhibitor alpha; Oxides; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2001 |
Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Synergism; Human T-lymphotropic virus 1; Humans; Interferon-alpha; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Membrane Potential, Mitochondrial; Mice; Mice, Inbred NOD; Mice, SCID; Time Factors; Xenograft Model Antitumor Assays | 2020 |